RxDoctor Payments Data

Lydia Rodriguez Ortiz, MD

Endocrinology · San Juan, PRNPI 1225088388

Payments from drug & device makers

$2,377in general payments, 2019–2025

Across 73 payments — averaging $32.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$560
  • E.r. Squibb & Sons, L.L.C.$274
  • Novo Nordisk$263
  • Boehringer Ingelheim$242
  • Johnson & Johnson$223
  • Abbott$223
  • plus $593 from 7 others

What the payments were for

  • Food & beverage$2,34599%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few endocrinology providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$21,895
Medicare patients
82
Services billed
191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol207$147,971
TrulicityDulaglutide109$110,672
OzempicSemaglutide85$90,673
SynthroidLevothyroxine Sodium942$71,149
JanuviaSitagliptin Phosphate97$65,678
JardianceEmpagliflozin52$60,070
MounjaroTirzepatide51$56,621
JanumetSitagliptin Phos/Metformin Hcl68$45,333
RybelsusSemaglutide35$39,840
ProliaDenosumab14$24,354
Xigduo XrDapaglifloz Propaned/Metformin36$24,308
TradjentaLinagliptin16$18,691
Janumet XrSitagliptin Phos/Metformin Hcl25$18,503
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog29$16,444
JentaduetoLinagliptin/Metformin Hcl18$10,560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$560$147,971207 claims
Novo NordiskOzempic, Rybelsus, Tresiba$263$134,821132 claims
MerckJanuvia, Janumet, Janumet Xr$25$129,514190 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Trijardy Xr$242$97,33699 claims
AbbVieSynthroid$22$71,149942 claims
AmgenProlia$208$24,35414 claims
Sanofi-aventis U.S. LLCLantus$128$7,39873 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few endocrinology providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other endocrinology in San Juan

Where these figures come from

Is this you, or does something look wrong? →